Scribe Therapeutics, Inc. (SCTX)
28.05
-4.95
(-15.00%)
USD |
NASDAQ |
Sep 21, 16:00
28.61
+0.56
(+2.00%)
After-Hours: 20:00
Scribe Therapeutics Enterprise Value : 745.36M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 745.36M |
| September 17, 2026 | 729.08M |
| September 16, 2026 | 671.53M |
| September 15, 2026 | 719.99M |
| September 14, 2026 | 677.59M |
| September 11, 2026 | 683.65M |
| September 10, 2026 | 678.53M |
| September 09, 2026 | 677.40M |
| September 08, 2026 | 713.94M |
| September 04, 2026 | 663.39M |
| September 03, 2026 | 703.90M |
| September 02, 2026 | 705.61M |
| September 01, 2026 | 669.64M |
| August 31, 2026 | 698.79M |
| August 28, 2026 | 659.03M |
| August 27, 2026 | 666.61M |
| August 26, 2026 | 720.75M |
| August 25, 2026 | 711.38M |
| August 24, 2026 | 825.82M |
| August 21, 2026 | 766.76M |
| August 20, 2026 | 742.14M |
| Date | Value |
|---|---|
| August 19, 2026 | 708.45M |
| August 18, 2026 | 633.86M |
| August 17, 2026 | 521.78M |
| August 14, 2026 | 513.07M |
| August 13, 2026 | 506.26M |
| August 12, 2026 | 556.24M |
| August 11, 2026 | 564.38M |
| August 10, 2026 | 592.58M |
| August 07, 2026 | 612.84M |
| August 06, 2026 | 601.67M |
| August 05, 2026 | 571.19M |
| August 04, 2026 | 538.25M |
| August 03, 2026 | 515.06M |
| July 31, 2026 | 489.41M |
| July 30, 2026 | 506.82M |
| July 29, 2026 | 468.20M |
| July 28, 2026 | 462.52M |
| July 27, 2026 | 479.75M |
| July 24, 2026 | 530.49M |
| July 23, 2026 | 404.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ionis Pharmaceuticals, Inc. | 7.495B |
| Cypherpunk Technologies, Inc. | 380.37M |
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.477M |
| Revenue (Quarterly) | 1.918M |
| Total Expenses (Quarterly) | 8.395M |
| EPS Diluted (Quarterly) | -0.3421 |
| Gross Profit Margin (Quarterly) | 59.07% |
| Profit Margin (Quarterly) | -337.7% |
| Earnings Yield | -7.30% |
| Normalized Earnings Yield | -7.330 |